Production (Stage)
Zivo Bioscience, Inc.
ZIVO
$13.50
-$0.44-3.16%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 662.71% | 166.95% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 662.71% | 166.95% | -- | -- |
| Cost of Revenue | -- | 718.18% | 187.01% | -- | -- |
| Gross Profit | -- | 558.54% | 131.71% | -- | -- |
| SG&A Expenses | 47.56% | -13.12% | 43.31% | 331.54% | -37.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 220.89% | -11.63% | 44.65% | 350.22% | -33.43% |
| Operating Income | -229.89% | 15.83% | -43.73% | -351.21% | 35.25% |
| Income Before Tax | -229.39% | 16.09% | -24.31% | -297.78% | 35.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -229.39% | 16.09% | -24.31% | -297.78% | 35.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -229.39% | 16.09% | -24.31% | -297.78% | 35.20% |
| EBIT | -229.89% | 15.83% | -43.73% | -351.21% | 35.25% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -141.40% | 54.37% | 36.73% | -110.86% | 62.99% |
| Normalized Basic EPS | -141.45% | 54.37% | 36.74% | -110.87% | 62.99% |
| EPS Diluted | -141.40% | 54.37% | 36.73% | -110.86% | 62.99% |
| Normalized Diluted EPS | -141.45% | 54.37% | 36.74% | -110.87% | 62.99% |
| Average Basic Shares Outstanding | 36.45% | 83.88% | 96.46% | 88.65% | 75.06% |
| Average Diluted Shares Outstanding | 36.45% | 83.88% | 96.46% | 88.65% | 75.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |